Clinical trial

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

NCT03355157

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-03-01

PhasePHASE4

Study timeline

Study start (actual)2018-03-01Date precision: day

Registry last updated2024-10-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Breast Cancerunresolved

Interventions

Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)DRUG

Sponsors & collaborators

GBG Forschungs GmbHlead sponsor

Pfizercollaborator

AMS Advanced Medical Services GmbHcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03355157 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.